Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2018

At a glance

  • Drugs Afatinib (Primary) ; Monalizumab (Primary) ; Palbociclib (Primary) ; Bleomycin; Bleomycin; Bleomycin; Docetaxel; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms UPSTREAM
  • Most Recent Events

    • 12 Nov 2018 According to Innate Pharma media release, data from thi study will be presented at SITC 2018 Annual Meeting .
    • 16 Oct 2018 According to Innate Pharma media release, data from thi study will be presented at the ESMO 2018 Congress.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top